- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
34 Nonspecifc, Unclassifable, and Rare Idiopathic Interstitial Pneumonia: Acute Interstitial Pneumonia, Respiratory Bronchiolitis… 599
Fig. 34.8 Chest radiograph from a patient with nonspeci c interstitial pneumonia showing bilateral interstitial in ltrates
ences in prognosis and treatment options between NSIP and UIP, a surgical lung biopsy should be performed to when HRCT suggests NSIP. In fact, this is the only way a de nitive diagnosis of NSIP can be made [53].
Histopathology
Bronchoscopy, while useful to rule out infection or other interstitial lung diseases, cannot make a speci c diagnosis of NSIP. When evaluated, broncho-alveolar lavage (BAL) ndings in NSIP often demonstrate increased lymphocyte counts and a reduced CD4:CD8 ratio (cellular NSIP), although some patients present with increased neutrophils and eosinophils ( brosing NSIP) [59, 60].
A surgical lung biopsy via VATS or thoracotomy is required to make a de nitive diagnosis of NSIP. The role of transbronchial cryobiopsy is not well de ned. Traditional transbronchial forceps lung biopsies have been reported to have a low diagnostic yield. Ideally, biopsy samples should be obtained from more than one lobe. The histopathology of NSIP is characterized by varied degrees of alveolar wall infammation andbrosis in a pattern that suggests temporal homogeneity, nottting the patterns of other IIPs [1, 61] (Fig. 34.10).
Temporal homogeneity is the major feature which distinguishes NSIP from UIP, the histologic pattern for IPF. There are three subgroups into which patients with NSIP are further classi ed. Group I has interstitial infammation as the primary nding (cellular NSIP). Group II has both infammation and brosis. Group III has brosis as the primary
a
b
Fig. 34.9 High-resolution computed tomography from the mid (panel a) and lower (panel b) lung elds of patient with nonspeci c interstitial pneumonia. The images demonstrate patchy areas of ground glass opaci cation, reticular thickening, and traction bronchiectasis. Some subpleural sparing of disease can be appreciated. Honeycombing is absent
nding ( brotic NSIP). This third group is differentiated from UIP by the absence of broblast foci and the presence of temporal homogeneity [47]. In clinical practice most pathologists simplify the division into two groups (cellular or brotic NSIP). Even expert pathologists have dif culty distinguishing between NSIP and UIP on a particular biopsy specimen [62, 63]. Further complicating this process, both
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
600 |
P. Ntiamoah et al. |
|
|
a
b
Fig. 34.10 At low power (panel a), brosing nonspeci c interstitial pneumonia demonstrates prominent, uniform septal thickening by mature collagen. At higher power (panel b), the septal thickening is due mainly to thick collagen with minimal infammation
NSIP and UIP patterns can be found in the same individual when biopsies are taken from multiple locations in 13%– 26% of patients [64, 65]. Those with discordant biopsy results have a prognosis similar to UIP, and should be considered to have UIP in all lobes (Fig. 34.9).
Clinical Course
Patients with NSIP tend to have a better prognosis and response to treatment compared to those with UIP/IPF [59, 61, 66]. This difference persists after adjusting for age, gender, smoking history, and physiologic variables. 5- and 10-year survival has been estimated as 43% and 15%, respectively, among patients with UIP, compared to approximately 90% 5-year survival and 30% 10-year survival rates among patients with NSIP with the brotic component [49]. Survival is the better in patients with a purely cellular pat-
tern, indicating that prognosis is determined by the degree of brosis [30, 31] That said, not all patients respond to therapy and progressive disease clearly occurs in some patients. The prognosis also depends on the presence of associated diseases and exposures and the ability to treat and mitigate these factors.
Treatment
Generally, the treatment and prognosis of NSIP vary signi - cantly and rely on the identi cation and management of associated conditions or environment/occupational, and drug exposures [67–69].
For SSc-ILD, which is commonly associated with NSIP pattern, studies have favored the use of mycophenolate mofetil over the use of cyclophosphamide due to similar ef - cacy with a more tolerable side effect pro le [70]. Other CTDs that may manifest ILD features include Sjogren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, and infammatory myositis. There are no guidelines or consensus on the treatment of ILD associated with those CTDs due to lack of controlled trials. However, corticosteroid is often the rst-line medication, while immunosuppressants such as azathioprine, cyclophosphamide, mycophenolate mofetil, or calcineurin inhibitors are considered as adjunctive, in steroid refractory cases, or in cases where corticosteroid is intolerable due to complications [71–73].
With regard to idiopathic NSIP, asymptomatic patients with mild disease may be followed without treatment [74]. However, for those with progressive disease or moderate to severe disease, corticosteroid treatment seems to be bene - cial in stabilizing pulmonary function [75, 76]. The optimal dose and duration of glucocorticoid therapy is not known, however, a starting dose of 1 mg/kg ideal body weight per day (maximum 60 mg/day) for 1 month followed by 40 mg/ day for an additional 2 months is recommended based on a compilation of studies [47, 54, 59, 61, 76].
Prednisone should be tapered to a goal of 5–10 mg daily to every other day in responders. After 12 months of treatment, practitioners can attempt to discontinue prednisone therapy. As prednisone is tapered or discontinued, some patients can experience clinical deterioration [66]; consideration of a longer prednisone course or steroid-sparing agents such as cyclophosphamide, azathioprine, or mycophenolate is appropriate in these cases. Combination therapy has also been shown by Kondoh et al. [65] to be effective in improving vital capacity percent predicted (VC % pred) in patients with idiopathic NSIP compared to IPF. Subjects in this study received methylprednisolone 1000 mg per day for 3 days weekly for 4 weeks, followed by combination therapy for 1 year with cyclophosphamide (1–2 mg/kg/day) plus low
34 Nonspecifc, Unclassifable, and Rare Idiopathic Interstitial Pneumonia: Acute Interstitial Pneumonia, Respiratory Bronchiolitis… 601
dose prednisolone 20 mg every other day [65]. After pulse therapy, 33% of patients with NSIP had improved VC % pred versus 15% with IPF [65]. After 1 year of combination therapy, 66% of patients with NSIP had improved versus 15% of the IPF group [65].
Cyclophosphamide has also been used as a sole agent with either known or suspected NSIP. Despite having severe, progressive disease, patients receiving IV cyclophosphamide had stable lung function at 6 months. The generally accepted dose of cyclophosphamide is 1–2 mg/kg/day orally, with a maximum dose of 200 mg or 750 mg/m2 body surface area.
When azathioprine is utilized, dosing is usually started at 50 mg daily, increased in 25–50 mg increments every 14 days to a dosage of 1–2 mg/kg/day (maximum dose of 150 mg daily) as long as blood counts and hepatic function are not impacted. Prior to initiation of this therapy, it is possible to evaluate patients for abnormal thiopurine methyltransferase (TPMT) enzymatic levels. If the TPMT level is low, a lower dose of azathioprine or an alternative immunosuppressive agent could be utilized.
For subset of patients with either idiopathic or secondary NSIP who suffer from progression regardless of aforementioned treatment, anti brotic agents may be an option. Nintedanib and pirfenidone are the two anti brotic agents available in the market which have successfully delayed the progression and suppressed acute exacerbation of idiopathic pulmonary brosis [77, 78]. Studies continue to explore the ef cacy and safety of anti brotic treatment in brotic NSIP due to multiple etiologies. Unfortunately, the trials have been limited or discontinued due to slow recruitment although some limited data suggested adding pirfenidone may slow the decline in FVC and thus disease progression [79].
In patients with severe, progressive NSIP or disease that is refractory to immunosuppressive therapy, lung transplantation can be considered [80]. Usually, patients should be referred for transplantation when the life-expectancy of the patient is between 24 and 36 months, however, poor quality of life can also be taken into consideration.
Unclassifable Interstitial Pneumonia
Even with multidisciplinary discussions at top institutions there are cases that remain unclassi able and now fall into its own category of IIP since the 2013 ATS/ERS update [3]. The ATS/ERS statement on the diagnosis and classi cation of idiopathic interstitial pneumonias lists the following areas that commonly lead to this situation including.
\1.\ Inadequate clinical, radiographic, or pathologic data.
\2.\ Major discordance between clinical, radiologic, and pathologic ndings in the following situations.
\(a)\ Previous therapy resulting in substantial alteration of radiologic of histologic ndings.
\(b)\ New entity, or unusual variant of recognized entity, not adequately characterized by the current classi cation.
\(c)\ Multiple HRCT and/or pathologic patterns that may be encountered in patients with IIP (2).
When these situations arise, the recommendation is to decide on treatment based on the most probable diagnosis. A 2012 retrospective series suggested that this situation may occur in approximately 10% of cases [69]. The main reasons for unclassi able ILD diagnosis were too old or frail for lung biopsy (52%), conficting data (18%), or mild/stable disease (9%). Patients with unclassi able disease had a better prognosis compared to IPF (HR 0.62, p = 0.04), but a similar survival to other non-IPF controls (HR 1.54, p = 0.12) [69].
References
1.\American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classi cation of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
2.\Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y. Acute interstitial pneumonia-Hamman-rich syndrome: clinical characteristics and diagnostic and therapeutic considerations. Anesth Analg. 2009;108(1):232–7.
3.\Travis WD, Costabel U, Hansell DM, et al. An of cial American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classi cation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733.
4.\Liu XY, Jiang ZF, Zhou CJ, PengY. Clinical features of 3 cases with acute interstitial pneumonia in children. Zhonghua Er Ke Za Zhi. 2011;49(2):98–102.
5.\Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol. 1986;10(4):256–67.
6.\Vourlekis JS, Brown KK, Cool CD, Young DA, Cherniack RM, King TE, et al. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore). 2000;79(6):369–78.
7.\Suh GY, Kang EH, Chung MP, Lee KS, Han J, Kitaichi M, et al. Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest. 2006;129(3):753–61.
8.\Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007;132:50.
9.\Mukhopadhyay S, Parambil JG. Acute interstitial pneumonia (AIP): relationship to Hamman-rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS). Semin Respir Crit Care Med. 2012;33:476.
10.\Olson J, Colby TV, Elliott CG. Hamman-rich syndrome revisited. Mayo Clin Proc. 1990;65(12):1538–48.
11.\Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest. 2006;130:553.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
602 |
P. Ntiamoah et al. |
|
|
12.\Nagai S, Kitaichi M, Izumi T. Classi cation and recent advances in idiopathic interstitial pneumonia. Curr Opin Pulm Med. 1998;4(5):256–60.
13.\Lim SY, Suh GY, Choi JC, et al. Usefulness of open lung biopsy in mechanically ventilated patients with undiagnosed diffuse pulmonary in ltrates: infuence of comorbidities and organ dysfunction. Crit Care. 2007;11:R93.
14.\Baumann HJ, Kluge S, Balke L, et al. Yield and safety of bedside open lung biopsy in mechanically ventilated patients with acute lung injury or acute respiratory distress syndrome. Surgery. 2008;143:426.
15.\Chuang ML, Lin IF, Tsai YH, et al. The utility of open lung biopsy in patients with diffuse pulmonary in ltrates as related to respiratory distress, its impact on decision making by urgent intervention, and the diagnostic accuracy based on the biopsy location. J Intensive Care Med. 2003;18:21.
16.\Tomiyama N, Muller NL, Johkoh T, Cleverley JR, Ellis SJ, Akira M, et al. Acute respiratory distress syndrome and acute interstitial pneumonia: comparison of thin-section CT ndings. J Comput Assist Tomogr. 2001;25(1):28–33.
17.\Ichikado K, Suga M, Muller NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography ndings between survivors and nonsurvivors. Am J Respir Crit Care Med. 2002;165(11):1551–6.
18.\Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford). 2000;39:1422.
19.\Robinson DS, Geddes DM, Hansell DM, et al. Partial resolution of acute interstitial pneumonia in native lung after single lung transplantation. Thorax. 1996;51:1158.
20.\Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med. 1974;291:755–8.
21.\Scheidl SJ, Kusej M, Flick H, Stacher E, Matzi V, Kovacs G, Popper HH, Costabel U, Olschewski H. Clinical manifestations of respiratory bronchiolitis as an incidental nding in surgical lung biopsies: a retrospective analysis of a large austrian registry. Respiration. 2016;91(1):26–33. https://doi.org/10.1159/000442053. Epub 2015 Dec 12
22.\Churg A, Müller NL, Wright JL. Respiratory bronchiolitis/interstitial lung disease: brosis, pulmonary function, and evolving concepts. Arch Pathol Lab Med. 2010;134(1):27–32. https://doi. org/10.5858/134.1.27.
23.\Kumar A, Cherian SV, Vassallo R, Yi ES, Ryu JH. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest. 2018;154(2):394–408. https://doi. org/10.1016/j.chest.2017.11.023. Epub 2017 Dec 5
24.\Attili AK, Kazerooni EA, Gross BH, Flaherty KR, Myers JL, Martinez FJ. Smoking-related interstitial lung disease: radiologic- clinical-pathologic correlation. Radiographics. 2008;28(5):1383– 96; discussion 96-8
25.\Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis. 1987;135(4):880–4.
26.\Woo OH, Yong HS, Oh YW, et al. Respiratory bronchiolitis- associated interstitial lung disease in a nonsmoker: radiologic and pathologic ndings. AJR Am J Roentgenol. 2007;188:W412.
27.\Flower M, Nandakumar L, Singh M, et al. Respiratory bronchiolitis- associated interstitial lung disease secondary to electronic nicotine delivery system use con rmed with open lung biopsy. Respirol Case Rep. 2017;5:e00230.
28.\King TE Jr. Respiratory bronchiolitis-associated interstitial lung disease. Clin Chest Med. 1993;14(4):693–8.
29.\Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE Jr, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest. 2007;131(3):664–71. https://doi.org/10.1378/chest.06-1885.
30.\Schwarz MI, King TE Jr, editors. Interstitial lung disease. 5th ed. Shelton, CT: People’s Medical Publishing House USA; 2010.
31.\Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM, Grenier PA, et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005;236(1):10–21.
32.\Konopka KE, Myers JL. A review of smoking-related interstitialbrosis, respiratory bronchiolitis, and desquamative interstitial pneumonia: overlapping histology and confusing terminology. Arch Pathol Lab Med. 2018;142(10):1177–81. https://doi.org/10.5858/ arpa.2018-0240-RA.
33.\Moon J, du Bois RM, Colby TV, Hansell DM, Nicholson AG. Clinical signi cance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax. 1999;54(11):1009–14.
34.\Ryu JH, Myers JL, Capizzi SA, Douglas WW, Vassallo R, Decker PA. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest. 2005;127(1):178–84.
35.\Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis- associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc. 1989;64(11):1373–80.
36.\Mukhopadhyay S, Aesif SW, Sansano I. Five simple reasons to discard DIP, or why we should stop calling dolphins big sh. J Clin Pathol. 2020;73(11):762–8. https://doi.org/10.1136/jclinpath- 2020-206669. Epub 2020 Aug 25
37.\Chakraborty RK, Basit H, Sharma S. Desquamative Interstitial Pneumonia. [Updated 2021 May 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526079/
38.\Diken ÖE, Şengül A, Beyan AC, Ayten Ö, Mutlu LC, Okutan O. Desquamative interstitial pneumonia: risk factors, laboratory and bronchoalveolar lavage ndings, radiological and histopathological examination, clinical features, treatment and prognosis. Exp Ther Med. 2019;17(1):587–95. https://doi.org/10.3892/etm.2018.7030.
39.\Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 1978;298(15):801–9.
40.\Hellemons ME, Moor CC, von der Thüsen J, Rossius M, Odink A, Thorgersen LH, Verschakelen J, Wuyts W, Wijsenbeek MS, Bendstrup E. Desquamative interstitial pneumonia: a systematic review of its features and outcomes. Eur Respir Rev. 2020;29(156):190181. https://doi.org/10.1183/16000617.01812019. Erratum in: Eur Respir Rev 2020 Aug 4;29(157)
41.\Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.
42.\Tazelaar HD, Wright JL, Churg A. Desquamative interstitial pneumonia. Histopathology. 2011;58(4):509–16.
43.\Yogo Y, Oyamada Y, Ishii M, Hakuno H, Fujita A, Yamauchi T, et al. A case of acute exacerbation of desquamative interstitial pneumonia after video-assisted thoracoscopic surgery (VATS). Nihon Kokyuki Gakkai Zasshi. 2003;41(6):386–91.
44.\Cottin V. Desquamative interstitial pneumonia: still orphan and not always benign. Eur Respir Rev. 2020;29(156):200183. https://doi. org/10.1183/16000617.0183-2020.
45.\Knyazhitskiy A, Masson RG, Corkey R, Joiner J. Bene cial response to macrolide antibiotic in a patient with desquamative interstitial pneumonia refractory to corticosteroid therapy. Chest. 2008;134(1):185–7. https://doi.org/10.1378/chest.07-2786.
46.\Verleden GM, Sels F, Van Raemdonck D, Verbeken EK, Lerut T, Demedts M. Possible recurrence of desquamative interstitial pneumonitis in a single lung transplant recipient. Eur Respir J. 1998;11:971–4. https://doi.org/10.1183/09031936.98.11040971.
47.\Katzenstein AL, Fiorelli RF. Nonspeci c interstitial pneumonia/brosis. Histologic features and clinical signi cance. Am J Surg Pathol. 1994;18(2):136–47.
34 Nonspecifc, Unclassifable, and Rare Idiopathic Interstitial Pneumonia: Acute Interstitial Pneumonia, Respiratory Bronchiolitis… 603
48.\Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR, et al. Idiopathic nonspeci c interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177(12):1338–47.
49.\Nayfeh AS, Chippa V, Moore DR. Nonspeci c Interstitial Pneumonitis. [Updated 2021 Mar 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518974/
50.\Fujita J, Ohtsuki Y, Yoshinouchi T, Yamadori I, Bandoh S, Tokuda M, et al. Idiopathic non-speci c interstitial pneumonia: as an "autoimmune interstitial pneumonia". Respir Med. 2005;99(2):234–40.
51.\Doria A, Mosca M, Gambari PF, Bombardieri S. De ning unclassi able connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol. 2005;32(2):213–5.
52.\Flaherty KR, Martinez FJ. Nonspeci c interstitial pneumonia. Semin Respir Crit Care Med. 2006;27(6):652–8.
53.\Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Muller N, Schwartz DA, et al. Radiologic ndings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003;124(4):1215–23.
54.\Silva CI, Muller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU. Nonspeci c interstitial pneumonia and idiopathic pulmonarybrosis: changes in pattern and distribution of disease over time. Radiology. 2008;247(1):251–9.
55.\Hartman TE, Swensen SJ, Hansell DM, Colby TV, Myers JL, Tazelaar HD, et al. Nonspeci c interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology. 2000;217(3):701–5.
56.\Nagai S, Kitaichi M, Itoh H, Nishimura K, Izumi T, Colby TV. Idiopathic nonspeci c interstitial pneumonia/ brosis: comparison with idiopathic pulmonary brosis and BOOP. Eur Respir J. 1998;12(5):1010–9.
57.\Veeraraghavan S, Latsi PI, Wells AU, Pantelidis P, Nicholson AG, Colby TV, et al. BAL ndings in idiopathic nonspeci c interstitial pneumonia and usual interstitial pneumonia. Eur Respir J. 2003;22(2):239–44.
58.\Lettieri CJ, Veerappan GR, Parker JM, Franks TJ, Hayden D, Travis WD, et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med. 2005;99(11):1425–30.
59.\Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004;59(6):500–5.
60.\Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, et al. Histopathologic variability in usual and nonspeci c interstitial pneumonias. Am J Respir Crit Care Med. 2001;164(9):1722–7.
61.\Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004;125(2):522–6.
62.\Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic signi cance of histopathologic subsets in idiopathic pulmonary brosis. Am J Respir Crit Care Med. 1998;157(1):199–203.
63.\Corte TJ, Ellis R, Renzoni EA, Hansell DM, Nicholson AG, du Bois RM, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-speci c interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):132–8.
64.\de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53–82.
65.\Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic
pulmonary brosis and brosing nonspeci c interstitial pneumonia. Eur Respir J. 2005;25(3):528–33.
66.\Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scienti c Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(7):745–55.
67.\Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Prognosis of brotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705–11.
68.\Navaratnam V, Ali N, Smith CJ, McKeever T, Fogarty A, Hubbard RB. Does the presence of connective tissue disease modify survival in patients with pulmonary brosis? Respir Med. 2011;105:1925– 30. https://doi.org/10.1016/j.rmed.2011.08.015.
69.\Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, et al. Prevalence and prognosis of unclassi able interstitial lung disease. Eur Respir J. 2014;43(5):1529–30.
70.\Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–19. https://doi. org/10.1016/S2213-2600(16)30152-7.
71.\Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397–405. https://doi. org/10.1378/chest.09-0444.
72.\Gutsche M, Rosen GD, Swigris JJ. Connective tissue disease- associated interstitial lung disease: a review. Curr Respir Care Rep. 2012;1:224–32.
73.\Solomon JJ, Fischer A. Connective tissue disease-associated interstitial lung disease: a focused review. J Intensive Care Med. 2015;30:392–400.
74.\Tomassetti S, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspeci c interstitial pneumonia: what is the optimal approach to management? Semin Respir Crit Care Med. 2016;37:378–94.
75.\Park IN, Jegal Y, Kim DS, Do KH, Yoo B, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Clinical course and lung function change of idiopathic nonspeci c interstitial pneumonia. Eur Respir J. 2009;33:68–76.
76.\Lee JY, Jin SM, Lee BJ, Chung DH, Jang BG, Park HS, Lee SM, Yim JJ, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW. Treatment response and long term follow-up results of nonspeci c interstitial pneumonia. J Korean Med Sci. 2012;27:661–7.
77.\Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. INPULSIS trial investigators, ef cacy and safety of nintedanib in idiopathic pulmonary brosis. N Engl J Med. 2014;370:2071–82.
78.\King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. ASCEND Study Group, a phase 3 trial of pirfenidone in patients with idiopathic pulmonary brosis. N Engl J Med. 2014;370:2083–92.
79.\Behr J, Neuser P, Prasse A, Kreuter M, Rabe K, Schade-Brittinger C, Wagner J, Ünther AG. Exploring ef cacy and safety of oral pirfenidone for progressive, nonIPF lung brosis (RELIEF)—a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017;17:122.
80.\Rampolla R. Lung transplantation: an overview of candidacy and outcomes. Ochsner J. 2014;14(4):641–8.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/